Bone-targeting agents in prostate cancer

Cancer and Metastasis Reviews

Volumn 33, Issue 2-3, 2014, Pages 619-628

  Suzman, Daniel L ^a   Boikos, Sosipatros A ^a   Carducci, Michael A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Bone metastases; Bone targeting agents; Prostate cancer

Indexed keywords

ABIRATERONE ACETATE; ATRASENTAN; BISPHOSPHONIC ACID DERIVATIVE; CABOZANTINIB; DASATINIB; DENOSUMAB; DOCETAXEL; ENDOTHELIN A RECEPTOR ANTAGONIST; ENZALUTAMIDE; LENALIDOMIDE; RADIUM CHLORIDE RA 223; SARACATINIB; STRONTIUM 89; TASQUINIMOD; THALIDOMIDE; ZIBOTENTAN; ZOLEDRONIC ACID; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT;

BONE MATRIX; BONE METASTASIS; CASTRATION RESISTANT PROSTATE CANCER; CELL DIFFERENTIATION; CELL SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM; HUMAN; METASTASIS FREE SURVIVAL; OSTEOBLAST; OSTEOCLAST; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STROMA; BONE; BONE NEOPLASMS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROSTATIC NEOPLASMS; SECONDARY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; MOLECULAR TARGETED THERAPY; OSTEOBLASTS; OSTEOCLASTS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84905102378     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9480-2     Document Type: Review

References (78)

1. Tannock, I. F., de Wit, R., Berry, W. R., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine, 351(15), 1502-1512. (Pubitemid 39315317)
2. Kantoff, P. W., Higano, C. S., Shore, N. D., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England Journal of Medicine, 363(5), 411-422.
3. de Bono, J. S., Oudard, S., Ozguroglu, M., et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet, 376(9747), 1147-1154.
4. Parker, C., Nilsson, S., Heinrich, D., et al. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. The New England Journal of Medicine, 369(3), 213-223.
5. Fizazi, K., Scher, H. I., Molina, A., et al. (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology, 13, 983-992.
6. Scher, H. I., Fizazi, K., Saad, F., et al. (2012). Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. Journal of Clinical Oncology, 30(Suppl 5), 1.
7. Paget, S. (1889). The distribution of secondary growths in cancer of the breast. The Lancet, 133(3421), 571-573.
8. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999). Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocrine Reviews, 20(3), 345-357. (Pubitemid 30649812)
9. Wada, T., Nakashima, T., Hiroshi, N., & Penninger, J. M. (2006). RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends in Molecular Medicine, 12(1), 17-25. (Pubitemid 43089652)
10. Shiozawa, Y., Pedersen, E. A., Havens, A. M., et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. The Journal of Clinical Investigation, 121(4), 1298.
11. Pedersen, E. A., Shiozawa, Y., Pienta, K. J., & Taichman, R. S. (2012). The prostate cancer bone marrow niche: more than just 'fertile soil'. Asian Journal of Andrology, 14(3), 423-427.
12. Schneider, A., Kalikin, L. M., Mattos, A. C., et al. (2005). Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology, 146(4), 1727-1736. (Pubitemid 40396881)
13. Shiozawa, Y., Pedersen, E. A., Patel, L. R., et al. (2010). GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia (New York, NY), 12(2), 116.
14. Taichman, R. S., Patel, L. R., Bedenis, R., et al. (2013). GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PloS one, 8(4), e61873.
15. Loberg, R. D., Gayed, B. A., Olson, K. B., & Pienta, K. J. (2005). A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. Journal of Cellular Biochemistry, 96(3), 439-446. (Pubitemid 41504643)
16. Guise, T. A., Mohammad, K. S., Clines, G., et al. (2006). Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clinical cancer research, 12(20), 6213s-6216s. (Pubitemid 44703792)
17. Small, E. J., Smith, M. R., Seaman, J. J., Petrone, S., & Kowalski, M. O. (2003). Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. Journal of Clinical Oncology, 21(23), 4277-4284. (Pubitemid 46621802)
18. Saad, F., Gleason, D. M., Murray, R., et al. (2004). Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of the National Cancer Institute, 96(11), 879-882. (Pubitemid 38807610)
19. Rosen, L. S., Gordon, D., Kaminski, M., et al. (2003). Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer, 98(8), 1735-1744. (Pubitemid 37238631)
20. Smith, M. R., Halabi, S., Ryan, C. J., et al. (2013). Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). ASCO Meeting Abstracts, 31(6-suppl), 27.
21. Wirth, M., Tammela, T., Huland, H., et al. (2008). Zoledronic acid for the prevention of bone metastases in high risk prostate cancer patients. A randomised, open label, multicentre study of the European Association of Urology (EAU) in cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO). European Urology Supplements, 7(3), 232.
22. Smith, M. R., Egerdie, B., Toriz, N. H., et al. (2009). Denosumab in men receiving androgen-deprivation therapy for prostate cancer. The New England Journal of Medicine, 361(8), 745-755.
23. Fizazi, K., Lipton, A., Mariette, X., et al. (2009). Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology, 27(10), 1564-1571.
24. Fizazi, K., Carducci, M., Smith, M., et al. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. The Lancet, 377(9768), 813-822.
25. Smith, M. R., Saad, F., Coleman, R., et al. (2012). Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. The Lancet, 379(9810), 39-46.
26. Summary minutes of the Oncologic Drugs Advisory Committee meeting. 2012.
27. Silberstein, E. B. (1996). Dosage and response in radiopharmaceutical therapy of painful osseous metastases. Journal of Nuclear Medicine, 37(2), 249-252.
28. Tu, S., Millikan, R. E., Mengistu, B., et al. (2001). Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. The Lancet, 357(9253), 336-341. (Pubitemid 32128538)
29. Sartor, O., Reid, R. H., Bushnell, D. L., Quick, D. P., & Ell, P. J. (2007). Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer, 109(3), 637-643. (Pubitemid 46190974)
30. Fizazi, K., Beuzeboc, P., Lumbroso, J., et al. (2009). Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. Journal of Clinical Oncology, 27(15), 2429-2435.
31. James, N. D., Pirrie, S., Barton, D., et al. (2013). Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). ASCO Meeting Abstracts, 31(18-suppl), LBA5000.
32. Nilsson, S., Franzén, L., Parker, C., et al. (2007). Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. The Lancet Oncology, 8(7), 587-594. (Pubitemid 46995621)
33. Nilsson, S., Strang, P., Aksnes, A. K., et al. (2012). A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. European Journal of Cancer, 48(5), 678-686.
34. Morris, M. J., Hammers, H. J., Sweeney, C., et al. (2013). Safety of radium-223 dichloride (ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): a phase I prostate cancer clinical trials consortium study. ASCO Meeting Abstracts, 31(15-suppl), 5021.
35. Carducci, M. A., Padley, R. J., Breul, J., et al. (2003). Effect of endothelin-A receptor blockade with atrasentan on tumor progression inmen with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. Journal of Clinical Oncology, 21(4), 679-689. (Pubitemid 46621903)
36. Schelman, W. R., Liu, G., Wilding, G., Morris, T., Phung, D., & Dreicer, R. (2011). A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Investigational New Drugs, 29(1), 118-125.
37. James, N. D., Caty, A., Payne, H., et al. (2010). Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized phase II trial. BJU International, 106(7), 966-973.
38. Nelson, J. B., Love, W., Chin, J. L., et al. (2008). Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer, 113(9), 2478-2487.
39. Nelson, J. B., Fizazi, K., Miller, K., et al. (2012). Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer, 118(22), 5709-5718.
40. Miller, K., Moul, J., Gleave, M., et al. (2013). Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases, 16(2), 187-192.
41. Akhavan, A., McHugh, K. H., Guruli, G., et al. (2006). Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia, 8(9), 725-732. (Pubitemid 44465524)
42. Kim, L. C., Song, L., & Haura, E. B. (2009). Src kinases as therapeutic targets for cancer. Nature Reviews Clinical Oncology, 6(10), 587-595.
43. Summy, J. M., & Gallick, G. E. (2003). Src family kinases in tumor progression and metastasis. Cancer and Metastasis Reviews, 22(4), 337-358. (Pubitemid 36791891)
44. Edwards, J. (2010). Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opinion on Investigational Drugs, 19(5), 605-614.
45. Tatarov, O., Mitchell, T. J., Seywright, M., Leung, H. Y., Brunton, V. G., & Edwards, J. (2009). SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clinical Cancer Research, 15(10), 3540-3549.
46. Nam, S., Kim, D., Cheng, J. Q., et al. (2005). Action of the src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Research, 65(20), 9185-9189. (Pubitemid 41507982)
47. Brownlow, N., Mol, C., Hayford, C., Ghaem-Maghami, S., & Dibb, N. (2008). Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia, 23(3), 590-594.
48. Lee, Y., Huang, C., Murshed, M., Chu, K., Araujo, J. C., & Ye, X. (2010). Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene, 29(22), 3196-3207.
49. Araujo, J. C., Trudel, G. C., Saad, F., Armstrong, A. J., Yu, E. Y., Bellmunt, J., et al. (2013). Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol, 14(13), 1307-1316.
50. Araujo, J. C., Mathew, P., Armstrong, A. J., et al. (2012). Dasatinib combined with docetaxel for castration-resistant prostate cancer. Cancer, 118(1), 63-71.
51. Anderson, G., Gries, M., Kurihara, N., et al. (2006). Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood, 107(8), 3098-3105.
52. Efstathiou, E., Troncoso, P., Wen, S., et al. (2007). Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clinical Cancer Research, 13(4), 1224-1231. (Pubitemid 46424064)
53. Vallet, S., Palumbo, A., Raje, N., et al. (2008). Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma, 49(7), 1238-1245. (Pubitemid 352015786)
54. Dahut, W. L., Gulley, J. L., Arlen, P. M., et al. (2004). Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Journal of Clinical Oncology, 22(13), 2532-2539. (Pubitemid 41103740)
55. Petrylak D, Fizazi K, Sternberg C, Budnik N, Wit Rd WP. A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lenalidomide in patients with castrate-resistant prostate cancer (CRPC): the MAINSAIL trial. 2012.
56. Chott, A., Sun, Z., Morganstern, D., et al. (1999). Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. The American Journal of Pathology, 155(4), 1271-1279. (Pubitemid 29488934)
57. Sulpice, E., Ding, S., Muscatelli-Groux, B., et al. (2009). Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biology of the Cell, 101(9), 525-539.
58. Tsai, S., Huang, Y., Yang, W., & Tang, C. (2012). Hepatocyte growth factor-induced BMP-2 expression is mediated by c-met receptor, FAK, JNK, Runx2, and p300 pathways in human osteoblasts. International Immunopharmacology, 13(2), 156-162.
59. Ryan, C. J., Rosenthal, M., Ng, S., et al. (2013). Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clinical Cancer Research, 19(1), 215-224.
60. Kelly, W. K., Halabi, S., Carducci, M., et al. (2012). Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. Journal of Clinical Oncology, 30(13), 1534-1540.
61. Smith, D. C., Smith, M. R., Sweeney, C., et al. (2013). Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. Journal of Clinical Oncology, 31(4), 412-419.
62. Isaacs, J. T., Pili, R., Qian, D. Z., et al. (2006). Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate, 66(16), 1768-1778. (Pubitemid 44893902)
63. Isaacs, J. T. (2010). The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opinion on Investigational Drugs, 19(10), 1235-1243.
64. Olsson, A., Björk, A., Vallon-Christersson, J., Isaacs, J. T., & Leanderson, T. (2010). Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Molecular Cancer, 9(1), 107.
65. Isaacs, J. T., Antony, L., Dalrymple, S. L., et al. (2013). Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Research, 73(4), 1386-1399.
66. Jennbacken, K., Welén, K., Olsson, A., et al. (2012). Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). Prostate, 72(8), 913-924.
67. Bratt, O., Häggman, M., Ahlgren, G., Nordle, Ö., Björk, A., & Damber, J. (2009). Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. British Journal of Cancer, 101(8), 1233-1240.
68. Pili, R., Häggman, M., Stadler, W. M., et al. (2011). Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology, 29(30), 4022-4028.
69. Armstrong, A. J., Haggman, M., Stadler, W. M., et al. (2012). Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: results of long-term follow-up of a randomized phase II placebo-controlled trial. Journal of Clinical Oncology, 30(15 Suppl), 4550.
70. Scher, H. I., Fizazi, K., Saad, F., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine, 367(13), 1187-1197.
71. Ryan, C. J., Smith, M. R., de Bono, J. S., et al. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England Journal of Medicine, 368(2), 138-148.
72. Logothetis, C. J., Basch, E., Molina, A., et al. (2012). Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. The lancet oncology., 13, 1210-7.
73. Tran, C., Ouk, S., Clegg, N. J., et al. (2009). Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 324(5928), 787-790.
74. Fizazi, K., Scher, H., Saad, F., et al. (2012). Impact of enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study. Annals of Oncology, 23, 295-296.
75. Jensen, A. B., Wynne, C., Ramirez, G., et al. (2010). The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clinical Breast Cancer, 10(6), 452-458.
76. Taichman, R. S. (2005). Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood, 105(7), 2631-2639.
77. Joyce, J. A., & Pollard, J.W. (2008). Microenvironmental regulation of metastasis. Nature Reviews Cancer, 9(4), 239-252.
78. Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer, 7(11), 834-846.